Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bio-Rad Laboratories's Revenue for the
three
months ended in Mar. 2026 was €512 Mil. Bio-Rad Laboratories's average Accounts Receivable for the
three
months ended in Mar. 2026 was €381 Mil.
Hence, Bio-Rad Laboratories's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.34.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bio-Rad Laboratories Receivables Turnover Related Terms
Bio-Rad Laboratories Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, PODD: Receivables Turnover Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a Receivables Turnover of 1.34 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bio-Rad Laboratories and its competitors. According to the industry distribution chart, Bio-Rad Laboratories ranks #381 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 47%.
Is Bio-Rad Laboratories' Receivables Turnover too high?
Bio-Rad Laboratories' current Receivables Turnover is 1.34. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Bio-Rad Laboratories' value of 1.34 is 75.7% below this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #381 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Receivables Turnover compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #381 out of 811 companies for Receivables Turnover. This puts Bio-Rad Laboratories in the upper half of its industry. The industry median Receivables Turnover is 5.51. Bio-Rad Laboratories' value of 1.34 is 75.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current Receivables Turnover of 1.34 is 75.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current Receivables Turnover is 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €277.30, compared to a current price of €263.20 — trading 5.1% below its estimated fair value. The current Receivables Turnover is 1.34 and 75.7% below the Medical Devices & Instruments industry median of 5.51. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Receivables Turnover is 1.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €263.20 is trading 5.1% below its estimated GF Value™ of €277.30.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
Receivables Turnover: 1.34
GF Value™: €277.30 vs. price of €263.20 (5.1% below fair value)
Industry Position: 75.7% below the Medical Devices & Instruments median (#381 of 811)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score
Get the complete analysis for FRA:BUWA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
